Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Implant Enables Women to Access Hip Resurfacing Surgery

By HospiMedica International staff writers
Posted on 07 Aug 2025

Hip resurfacing is a less invasive alternative to total hip replacement, often preferred for younger and more active patients as it preserves more of the natural bone and allows greater post-operative mobility. More...

However, this option has long been unavailable to women and men with smaller femoral heads—defined as less than 50 millimeters in diameter—due to complications associated with existing metal implants. These implants were not optimized for women’s hip anatomy and often released metal particles into the body, leading to tissue reactions and high failure rates. As a result, women and smaller men have been excluded from this form of treatment, despite making up a significant portion of hip replacement patients. Now, a new implant design addresses these limitations by offering a safer and anatomically compatible option, enabling broader access to hip resurfacing surgery.

The H1 implant, developed by Embody Orthopedic (London, UK), is designed using ceramic rather than metal to coat the two faces of the hip joint, the implant avoids particle-related side effects and is compatible with the natural contours of both female and male joints. Ceramic is more wear-resistant and biocompatible, reducing the risk of complications. This innovative solution allows resurfacing for individuals previously deemed ineligible for the procedure.

The device enables the retention of living bone structure, supporting strength and flexibility post-surgery, which aids in maintaining health and mobility. In clinical trials involving over 100 patients, those who received the implant were able to resume physical activities such as swimming and cycling within six weeks of surgery. Long-term monitoring of patient performance has shown continued improvement, with some individuals achieving even better outcomes five years after surgery compared to their first-year results.

With over 100 patients now more than five years post-operation, the H1 implant appears to perform comparably to other well-designed hip resurfacing devices. The device has now been awarded the CE mark—the first hip resurfacing device to be certified under the European Union’s new Medical Device Regulation (MDR) guidelines—and is the first non-metal resurfacing implant approved globally. It will now be available across Europe and in other CE mark-recognizing countries.

"We are really pleased that our new implant enables women and smaller men to benefit from hip resurfacing. Resurfacing has always been an effective option for active and younger patients who don’t need a total hip replacement, but for 10 years its use has been restricted to large men," said Professor Justin Cobb, Co-Founder of Embody Orthopedic. “Alongside improving the picture for women, the new implant also reduces the risk of side effects.”

Related Links:
Embody Orthopedic


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.